Pragmatic Design of Randomized Clinical Trials for Heart Failure

Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 62, e147, 10.1016/j.jacc.2013.05.019

Harinstein, 2015, Site selection for heart failure clinical trials in the USA, Heart Fail Rev, 20, 375, 10.1007/s10741-015-9473-z

Samman Tahhan, 2018, Design elements and enrollment patterns of contemporary trials in heart failure with preserved ejection fraction: a systematic review, J Am Coll Cardiol HF, 6, 714

Butler, 2013, Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial, J Am Coll Cardiol, 61, 571, 10.1016/j.jacc.2012.10.025

Teerlink, 2013, Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial, Lancet, 381, 29, 10.1016/S0140-6736(12)61855-8

Gheorghiade, 2013, Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial, JAMA, 309, 1125, 10.1001/jama.2013.1954

Packer, 2017, Effect of ularitide on cardiovascular mortality in acute heart failure, N Engl J Med, 376, 1956, 10.1056/NEJMoa1601895

Metra, 2019, Effects of serelaxin in patients with acute heart failure, N Engl J Med, 381, 716, 10.1056/NEJMoa1801291

Summer, 2012, Physician perception of the impact of productivity measures on academic practice, Arch Intern Med, 172, 967, 10.1001/archinternmed.2012.1579

Greene, 2016, Influence of clinical trial site enrollment on patient characteristics, protocol completion, and end points: insights from the ASCEND-HF trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure), Circ Heart Fail, 9, 10.1161/CIRCHEARTFAILURE.116.002986

Greene, 2019, Representativeness of a heart failure trial by race and sex: results from ASCEND-HF and GWTG-HF, J Am Coll Cardiol HF, 7, 980

Tahhan, 2018, Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: a systematic review, JAMA Cardiol, 3, 1011, 10.1001/jamacardio.2018.2559

Martin, 2017, How much do clinical trials cost?, Nat Rev Drug Discov, 16, 381, 10.1038/nrd.2017.70

Moore, 2018, Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015–2016, JAMA Intern Med, 178, 1451, 10.1001/jamainternmed.2018.3931

Samman Tahhan, 2018, Evolving landscape of clinical trials in heart failure: patient populations, endpoint selection, and regions of enrollment, Curr Heart Fail Rep, 15, 10, 10.1007/s11897-018-0374-z

Psotka, 2019, Heart failure site-based research in the United States: results of the Heart Failure Society of America Research Network Survey, J Am Coll Cardiol HF, 7, 431

Loudon, 2015, The PRECIS-2 tool: designing trials that are fit for purpose, BMJ, 350, h2147, 10.1136/bmj.h2147

Mentz, 2016, Good clinical practice guidance and pragmatic clinical trials: balancing the best of both worlds, Circulation, 133, 872, 10.1161/CIRCULATIONAHA.115.019902

Federspiel, 2016, Comparing inverse probability of treatment weighting and instrumental variable methods for the evaluation of adenosine diphosphate receptor inhibitors after percutaneous coronary intervention, JAMA Cardiol, 1, 655, 10.1001/jamacardio.2016.1783

Hernandez, 2012, Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction, JAMA, 308, 2097, 10.1001/jama.2012.14795

Buggey, 2015, A reappraisal of loop diuretic choice in heart failure patients, Am Heart J, 169, 323, 10.1016/j.ahj.2014.12.009

Greene, 2018, Potential advantages of torsemide in patients with heart failure: more than just a 'water pill'?, Eur J Heart Fail, 20, 471, 10.1002/ejhf.1024

Kasama, 2006, Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure, Heart, 92, 1434, 10.1136/hrt.2005.079764

Lopez, 2004, Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure, J Am Coll Cardiol, 43, 2028, 10.1016/j.jacc.2003.12.052

Lopez, 2007, Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure, J Am Coll Cardiol, 50, 859, 10.1016/j.jacc.2007.04.080

Murray, 2001, Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure, Am J Med, 111, 513, 10.1016/S0002-9343(01)00903-2

Cosin, 2002, Torasemide in chronic heart failure: results of the TORIC study, Eur J Heart Fail, 4, 507, 10.1016/S1388-9842(02)00122-8

Muller, 2003, Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV--efficacy and quality of life, Eur J Heart Fail, 5, 793, 10.1016/S1388-9842(03)00150-8

Greene, 2018, Reassessing the role of surrogate end points in drug development for heart failure, Circulation, 138, 1039, 10.1161/CIRCULATIONAHA.118.034668

Bikdeli, 2013, Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives?, J Am Coll Cardiol, 61, 1549, 10.1016/j.jacc.2012.12.043

Lachin, 1999, Worst-rank score analysis with informatively missing observations in clinical trials, Control Clin Trials, 20, 408, 10.1016/S0197-2456(99)00022-7

Bang, 2000, Estimating medical costs with censored data, Biometrika, 87, 329, 10.1093/biomet/87.2.329

Wijeysundera, 2009, Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials, J Clin Epidemiol, 62, 13, 10.1016/j.jclinepi.2008.07.006

Greene, 2018, Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial, Eur J Heart Fail, 20, 1760, 10.1002/ejhf.1310

Alvarez-Garcia, 2020, Prognostic impact of prior heart failure in patients hospitalized with COVID-19, J Am Coll Cardiol, 76, 2334, 10.1016/j.jacc.2020.09.549

Greene, 2015, The vulnerable phase after hospitalization for heart failure, Nat Rev Cardiol, 12, 220, 10.1038/nrcardio.2015.14